Mankind Pharma board to consider fund raising

Written by Ruchika Sharma Published On 2024-09-18T16:33:26+05:30 | Updated On 18 Sept 2024 4:33 PM IST

delhi high court relief to mankind in infringement case against aquakind

New Delhi: Mankind Pharma has informed in a BSE filing that a meeting of Board of Directors of the Company will be held on September 20, 2024, inter-alia to consider and approve the raising of funds by way of issue of non-convertible debentures, commercial papers, other debt securities or any other security or any combination thereof for an amount as may be decided by the Board.

Mankind Pharma is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations and consumer healthcare products.

The company in an investor presentation had stated that it looks to grow consumer healthcare business through line extensions, new launches, and premiumization, by leveraging existing brand equity, additional distribution models.

Mankind also looks to increase the value of prescriptions in the existing market and increase the share of chronic segment by growing presence in existing therapies, as per the presentation.

Read also: Submit Phase I/Phase II clinical trial data: CDSCO Panel Tells Mankind on Dydrogesterone Injection 5mg/ml

Founded in 1991 and commenced operation in 1995, Mankind Pharma is a pharmaceutical company engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products.

mankind phamamankind pharna news

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751